Pfizer and its German pharmaceutical partner BioNTech announced they are submitting a request to the U.S. Food and Drug Administration (FDA) to authorize extra-low doses of their COVID-19 vaccine for children 6 months through 4 years of age. The FDA had urged Pfizer-BioNTech to apply for the Emergency Use Authorization (EUA) earlier than the companies had planned. If the FDA grants the authorization, it would be the first COVID-19 vaccine for the age group in the United States. A decision is expected as soon as by the end of February. The intended dosage of the jab for this age group is one-tenth of that given to adults (30 µg), and one-third of that given to children aged 5–11 (10 µg). “This application is for authorization of the first two 3µg doses of a planned three-dose primary series in this age group,” the companies announced in a statement on Feb. 1. “Data on a third dose …